Guardian Asset Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Guardian Asset Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$397K	Buy	799 +29	+4%	+$12.9K	0.18%	87
2026 Q1	$344K	Sell	770 -115	-13%	-$53.6K	0.2%	78
2025 Q4	$401K	Buy	885 +10	+1%	+$4.31K	0.21%	74
2025 Q3	$343K	Sell	875 -92	-10%	-$38.4K	0.18%	81
2025 Q2	$431K	Buy	967 +67	+7%	+$30.9K	0.25%	68
2025 Q1	$436K	Buy	900 +105	+13%	+$48.9K	0.28%	66
2024 Q4	$320K	Hold	795	–	–	0.21%	81
2024 Q3	$370K	Buy	795 +93	+13%	+$44.7K	0.25%	75
2024 Q2	$329K	Buy	702 +42	+6%	+$18.2K	0.24%	74
2024 Q1	$276K	Buy	+660	New	+$279K	0.23%	84

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

Guardian Asset Advisors's VRTX Position: Q2 2026 in Review

Guardian Asset Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 3.8% in Q2 2026, buying an estimated $12.9K and bringing the position to 799 shares worth $397K. The position accounts for 0.18% of the portfolio, ranked #87.

Guardian Asset Advisors first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $436K in Q1 2025. 536 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Guardian Asset Advisors held 799 shares of Vertex Pharmaceuticals worth $397K as of Q2 2026.
Guardian Asset Advisors bought 29 Vertex Pharmaceuticals shares in Q2 2026, an estimated $12.9K.
Vertex Pharmaceuticals made up 0.18% of Guardian Asset Advisors's portfolio in Q2 2026, its #87 holding.
Guardian Asset Advisors first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
Guardian Asset Advisors's Vertex Pharmaceuticals position peaked at $436K in Q1 2025.
536 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Guardian Asset Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.